- Home
- FERA vs CAPR Comparison
FERA vs CAPR Comparison
Compare FERA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- CAPR
- Stock Information
- Founded
- FERA 2024
- CAPR 2005
- Country
- FERA Cayman Islands
- CAPR United States
- Employees
- FERA N/A
- CAPR N/A
- Industry
- FERA
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FERA
- CAPR Health Care
- Exchange
- FERA Nasdaq
- CAPR Nasdaq
- Market Cap
- FERA 317.4M
- CAPR 324.6M
- IPO Year
- FERA 2025
- CAPR N/A
- Fundamental
- Price
- FERA $10.13
- CAPR $6.28
- Analyst Decision
- FERA
- CAPR Strong Buy
- Analyst Count
- FERA 0
- CAPR 8
- Target Price
- FERA N/A
- CAPR $24.75
- AVG Volume (30 Days)
- FERA 3.0
- CAPR 1.4M
- Earning Date
- FERA 01-01-0001
- CAPR 08-11-2025
- Dividend Yield
- FERA N/A
- CAPR N/A
- EPS Growth
- FERA N/A
- CAPR N/A
- EPS
- FERA N/A
- CAPR N/A
- Revenue
- FERA N/A
- CAPR $13,392,150.00
- Revenue This Year
- FERA N/A
- CAPR N/A
- Revenue Next Year
- FERA N/A
- CAPR $6,061.53
- P/E Ratio
- FERA N/A
- CAPR N/A
- Revenue Growth
- FERA N/A
- CAPR N/A
- 52 Week Low
- FERA $10.00
- CAPR $3.98
- 52 Week High
- FERA $10.60
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- CAPR 36.33
- Support Level
- FERA N/A
- CAPR $6.17
- Resistance Level
- FERA N/A
- CAPR $7.30
- Average True Range (ATR)
- FERA 0.00
- CAPR 0.43
- MACD
- FERA 0.00
- CAPR -0.11
- Stochastic Oscillator
- FERA 0.00
- CAPR 4.53
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.